Cedars-Sinai Medical Center's Institutional Review Board (IRB) is the entity responsible for overseeing all research activities involving human subjects conducted at Cedars-Sinai. The IRB operates under a Federalwide Assurance (FWA) - approved by the Office of Human Research Protections of the U.S. Department of Health and Human Services - that requires Cedars-Sinai to conduct human subjects research in accordance with the Belmont principles of respect for persons, beneficence and justice. It also follows the guidance published by the U.S Food and Drug Administration (FDA) for institutional review boards and clinical investigators.
There are three IRBs at Cedars-Sinai. The mission of the three IRBs is to protect the rights and welfare of human subjects involved in research at Cedars-Sinai. In order to accomplish this mission, the IRBs conduct thorough reviews of each research study prior to its initiation and at regular intervals thereafter to ensure that the research conforms to and abides by all applicable ethical principles and federal, state and institutional regulations. In addition, the IRBs monitor the conduct of research after approval.
The Office of Research Compliance is the administrative unit of the IRB. The Director of the Office of Research Compliance serves as the designated institutional Human Protection Administrator. Under the leadership of the Director of the Office of Research Compliance, IRB staff members perform duties that support the protection of the rights and welfare of human subjects involved in research activities conducted at Cedars-Sinai.
If you have any questions regarding the IRB functions and review process, you can contact:
Office of Research Compliance
Phone: (310) 423-3783